Hims & Hers Health (NYSE:HIMS) CFO Oluyemi Okupe Sells 4,938 Shares

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) CFO Oluyemi Okupe sold 4,938 shares of the company's stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $29.99, for a total transaction of $148,090.62. Following the completion of the transaction, the chief financial officer owned 264,117 shares of the company's stock, valued at approximately $7,920,868.83. This trade represents a 1.84% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

• Hims & Hers’ Revenue Beat Came With a Profitability Problem

Oluyemi Okupe also recently made the following trade(s):

• On Thursday, June 18th, Oluyemi Okupe sold 55,383 shares of Hims & Hers Health stock. The stock was sold at an average price of $35.09, for a total transaction of $1,943,389.47.
• On Monday, August 17th, Oluyemi Okupe sold 9,388 shares of Hims & Hers Health stock. The shares were sold at an average price of $27.89, for a total value of $261,831.32.
• On Monday, July 6th, Oluyemi Okupe sold 7,163 shares of Hims & Hers Health stock. The shares were sold at an average price of $36.49, for a total value of $261,377.87.
• On Monday, June 22nd, Oluyemi Okupe sold 18,197 shares of Hims & Hers Health stock. The stock was sold at an average price of $34.03, for a total value of $619,243.91.

Hims & Hers Health Stock Performance

---

---

Shares of HIMS stock opened at $31.95 on Friday. The company has a market capitalization of $7.45 billion, a P/E ratio of -50.71 and a beta of 2.40. The business's 50 day moving average is $32.23 and its two-hundred day moving average is $26.09. The company has a current ratio of 0.93, a quick ratio of 0.87 and a debt-to-equity ratio of 4.21. Hims & Hers Health, Inc. has a 12-month low of $13.74 and a 12-month high of $65.30.

• The FTC Is Suing Hims & Hers Health—Here's Why Investors Shouldn't Panic

Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its quarterly earnings data on Monday, August 10th. The company reported ($0.37) EPS for the quarter, missing analysts' consensus estimates of ($0.05) by ($0.32). The business had revenue of $753.21 million during the quarter, compared to analysts' expectations of $698.90 million. Hims & Hers Health had a negative net margin of 5.51% and a negative return on equity of 6.51%. The firm's quarterly revenue was up 38.2% compared to the same quarter last year. During the same quarter last year, the firm earned $0.17 earnings per share. Analysts expect that Hims & Hers Health, Inc. will post -0.05 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the stock. Barclays upped their price objective on shares of Hims & Hers Health from $29.00 to $39.00 and gave the stock an "overweight" rating in a research report on Wednesday, June 17th. Bank of America lifted their target price on shares of Hims & Hers Health from $30.00 to $32.00 and gave the company a "neutral" rating in a research report on Tuesday, August 11th. Jefferies Financial Group set a $24.50 target price on shares of Hims & Hers Health in a research note on Tuesday, May 12th. Needham & Company LLC upped their price target on shares of Hims & Hers Health from $35.00 to $42.00 and gave the stock a "buy" rating in a research report on Tuesday, August 11th. Finally, TD Cowen raised their price target on shares of Hims & Hers Health from $25.00 to $30.00 and gave the company a "hold" rating in a research note on Tuesday, August 11th. Four investment analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Hims & Hers Health has a consensus rating of "Hold" and a consensus target price of $32.43.

• Bearish Pressure Is Building Around These 3 Stocks

Get Our Latest Stock Analysis on Hims & Hers Health

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in HIMS. Binnacle Investments Inc acquired a new stake in Hims & Hers Health during the 3rd quarter worth $28,000. Versant Capital Management Inc grew its holdings in shares of Hims & Hers Health by 801.2% during the second quarter. Versant Capital Management Inc now owns 748 shares of the company's stock worth $26,000 after buying an additional 665 shares in the last quarter. MassMutual Private Wealth & Trust FSB lifted its stake in shares of Hims & Hers Health by 70.0% in the second quarter. MassMutual Private Wealth & Trust FSB now owns 775 shares of the company's stock worth $27,000 after buying an additional 319 shares in the last quarter. Silicon Valley Capital Partners purchased a new position in shares of Hims & Hers Health in the third quarter worth about $48,000. Finally, Bogart Wealth LLC boosted its position in Hims & Hers Health by 235.8% during the fourth quarter. Bogart Wealth LLC now owns 900 shares of the company's stock worth $29,000 after acquiring an additional 632 shares during the last quarter. Hedge funds and other institutional investors own 63.52% of the company's stock.

Hims & Hers Health News Summary

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: CEO Andrew Dudum defended Hims & Hers against the FTC’s allegations and said the company’s strategy could improve patient access and affordability. He also discussed a potential AI health coach that could support medication adherence, creating a possible long-term technology catalyst. Hims & Hers rejects privacy allegations
• Positive Sentiment: Some investors continue to view the recent margin weakness as an opportunity, citing Hims & Hers’ 38.2% year-over-year revenue growth and potential expansion into testosterone, peptides, branded GLP-1 treatments and international markets. However, execution and profitability remain important hurdles. Hims & Hers: Buying the Margin Dip
• Neutral Sentiment: Recent insider filings show sales by CFO Oluyemi Okupe, Deborah M. Autor and Soleil Boughton. The transactions were conducted under pre-arranged Rule 10b5-1 plans, and several sales were intended to cover tax obligations from vested equity awards. Because insiders retained substantial positions, the filings are a limited bearish signal rather than clear evidence of weakening confidence. SEC insider transaction filing
• Neutral Sentiment: Analyst sentiment remains mixed. The consensus rating is “Hold,” while Needham raised its price target to $42 and maintained a Buy rating. The split view reflects strong sales growth but concerns about losses, margins and the GLP-1 business strategy.
• Negative Sentiment: The FTC litigation and new investigations by Kaplan Fox and Berger Montague add potential legal costs, compliance requirements and reputational risk. The investigations focus on alleged sharing of private health data, deceptive billing and difficult subscription cancellations, keeping regulatory uncertainty over the stock. Kaplan Fox investigation
• Negative Sentiment: Hims & Hers’ latest quarter showed a larger-than-expected loss of $0.37 per share versus the $0.05 consensus estimate, despite revenue exceeding expectations. The earnings miss and negative profitability metrics could limit the stock’s upside until margins improve.

About Hims & Hers Health

(Get Free Report)

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients' doorsteps.

The company's product portfolio addresses key areas of men's and women's health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.

Featured Articles

• Five stocks we like better than Hims & Hers Health
• Moderna’s 177% Surge Has Investors Asking What Comes Next
• 3 Energy Stocks Raising Dividends as the Sector Surges
• 5 Reasons the S&P 500 Could Keep Rallying Through Year-End
• Walmart's Post-Earnings Drop Could Be a Buying Opportunity

This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].